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Abstract: There is, to date, no medical therapy that modifies the decline in lung function
that occurs in COPD. As the disease becomes more severe, exacerbations of COPD become
increasingly common, affecting patient quality of life and increasing health care costs.
Mucolytic agents, through their actions on inflammatory and oxidative pathways, have potential
benefits in COPD. This paper reviews the randomized controlled trial (RCT) evidence for the
effectiveness of at least 2 months of daily therapy with oral mucolytics in COPD. Based on
evidence from 26 RCTs, mucolytics reduce exacerbations by up to 0.8 exacerbations per
year, with a greater effect in patients with more severe COPD. This effect appears to be of a
similar magnitude to the reduction in exacerbations seen with tiotropium and inhaled
corticosteroids (ICS), but RCTs that compared the agents would be required to confirm this.
Mucolytics do not affect the rate of lung function decline, but they do not have any significant
adverse effects. Mucolytic treatment should be considered in: patients with more severe COPD
who have frequent or prolonged exacerbations; those who are repeatedly admitted to hospital;
or in those patients with frequent exacerbations who are unable to take tiotropium or ICS.
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Interest is increasingly being directed at finding therapies that reduce the frequency
and severity of COPD exacerbations and, in so doing, relieve associated morbidity
and reduce health care expenditure (Friedman and Hilleman 2001).
Medicines in the class broadly defined as “mucolytics” are agents that have long
been used in mainland Europe for chronic bronchitis (CB) and COPD, yet they are
seldom used in other parts of the world including Australia and New Zealand.
Potentially useful mechanisms of action of mucolytics in COPD include: thinning or
regulation of production of mucus, promotion of mucociliary clearance and
expectoration, and antioxidant or antibacterial activity. The reader is referred to
detailed accounts of mucus pathophysiology and the pharmacology of mucoactive
drugs (Rogers 2002), and the relevance of the antioxidant properties of N-
acetylcysteine (NAC) in COPD (Dekhuijzen 2004).
Cochrane systematic review
A Cochrane systematic review evaluating the clinical effects of treatment with
mucolytic agents in patients was first reported in 1999 and updated in 2001 and 2003
(Poole and Black 2003). To be eligible for inclusion in this review, studies had to be
randomized, double-blind, placebo-controlled studies of oral mucolytics administered
regularly for a period of at least 2 months to adults with COPD or CB. The primary
outcomes were the number of exacerbations, and days sick or on antibiotics. Secondary
outcomes were lung function and adverse events.
Extensive searching on 3 occasions identified 27 eligible studies, but 4 of these
did not have information on the primary outcomes. The remaining 23 studies were
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included in the review. Subjects in the 21 earlier studies had
CB, which was most often defined as having cough
productive of sputum on most days for a minimum of 3
months for at least 2 consecutive years (Fletcher and Pride
1984). In the other 2 studies, subjects had COPD, a disease
that is now defined by expert panels in the Global Initiative
for Obstructive Lung Disease (GOLD) workshops as “a
disease state characterized by airflow limitation that is not
fully reversible. It is usually progressive and associated with
an abnormal inflammatory response of the lungs to noxious
particles and gases”. (Pauwels et al 2001). It is likely that
most of the subjects with CB in the earlier studies also had
COPD as most were smokers and, when lung function was
measured, there was evidence of airway obstruction. In 12
of the studies the mucolytic used was NAC. Other study
treatments were ambroxol (2), carbocysteine (2), sobrerol,
carbocysteine sobrerol, letosteine, cithiolone, iodinated
glycerol, N-isobutyrylcysteine (NIC), and myrtol. Ten of
the studies were conducted in Italy, 3 each in Scandinavia
and Germany, 4 in the UK, 2 in several European countries,
and 1 in the US. Six of the studies had a duration of less
than 3 months. All of the 23 randomized controlled trials
(RCTs) had a Jadad quality score of at least 2 out of 5 and
20 had a score of 3 or more (Moher et al 1996).
Meta-analysis of the included trials produced the finding
of a small but statistically significant effect of mucolytics
on exacerbation rates of 0.066 exacerbations per month (95%
confidence interval [CI] –0.054 to –0.077). The annualized
exacerbation rate of 2.7 per patient per year in the control
group would thus be reduced by 0.79 exacerbations per
patient per year with mucolytic treatment, which equates to
a 29% reduction. Even though this approach will
overestimate the number of exacerbations per year since
more exacerbations occur during the winter months when
the studies were performed, a reduction of 0.8 exacerbations
per year would be clinically important. Evidence from the 2
studies with more severe subjects (mean FEV1 of less than
50% of predicted) showed a reduction in the exacerbation
rate of 0.13 per patient per month (1.56 per year), which is
double that seen when all the studies were pooled. NAC is
the mucolytic that has been most extensively studied;
however, other mucolytics as a group had similar effects on
exacerbation rates.
In the meta-analysis of studies in the Cochrane review,
subjects who received mucolytic therapy were twice as likely
to remain exacerbation-free in the study period (odds ratio
[OR] 2.22, 95% CI 1.93 to 2.54) than if they had received
placebo. The number needed to treat (NNT) for 3–6 months
to achieve 1 less exacerbation over that time was 6.
Treatment with mucolytics resulted in 0.56 days less of
disability per patient per month (95% CI –0.77 to –0.35).
This finding was based on a smaller number of studies (6)
but was supported by 4 other studies where mean values
were reported without standard deviations. All 4 studies
showed a reduction in days of disability with mucolytics of
between 0.3 and 3.9 days per patient per month. A similar-
sized effect was seen for days on antibiotics as well. These
findings suggest that the exacerbations that do occur while
taking mucolytics are less serious or less prolonged.
The findings in the Cochane review are supported by 2
other systematic reviews of the effects of NAC in CB. The
larger of these included 11 RCTs (Stey et al 2000). Overall,
those treated with NAC were more likely to remain
exacerbation-free (OR 1.56, 95% CI 1.37 to 1.77), with a
NNT of 5.8 (95% CI 4.5 to 8.1). Subjects were more likely
to report an improvement in symptoms with NAC (OR 1.78,
95% CI 1.54 to 2.05) than with placebo. The second review
(Grandjean et al 2000b) analyzed 9 trials that had been
included in both the Stey and the Cochrane review and
confirmed the significant effect on exacerbations
(standardized mean difference –1.37, 95% CI –1.5 to
–1.25).
For the periods of the studies included in the Cochrane
review (2–24 months), there was, however, no convincing
evidence of any beneficial effect of mucolytic agents on lung
function.
The Cochrane review concluded that treatment with
mucolytics produced a small reduction in exacerbations and
a somewhat greater reduction in the total number of days of
disability in a population of patients with CB or relatively
mild COPD. It was felt that a value judgement of physician
and patient was required as to whether the benefits were
sufficient to warrant the routine use of regular mucolytics
in these patients.
The reviewers called for future studies to address the
value of mucolytic therapy in patients who had 4 or more
exacerbations a year or who have prolonged or severe
exacerbations or repeated admissions to hospital with
exacerbations of COPD.
The Cochane review is currently undergoing a further
update to take account of recent new studies of mucolytics
in COPD (Malerba et al 2004; Moretti et al 2004; Decramer
et al 2005).International Journal of COPD 2006:1(2) 125
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Recent RCTs of mucolytics
The findings of a 3-year RCT of NAC 600 mg per day vs
placebo in 523 subjects with COPD have been keenly
awaited (Decramer et al 2005). This rigorously conducted
study took place in 50 European centers across 10 countries.
The primary endpoints related to yearly decrease in lung
function, and secondary endpoints to quality of life and cost
utility. The study included men and women from 40 to 75
years, with a mean age of 62 years. All had smoking-related
COPD, with an FEV1/VC ratio of less than 88% in men and
89% in women, and minimal reversibility in FEV1. The mean
FEV1 was 1.65 L (57% predicted) and mean reversibility
with bronchodilator, 4%. Subjects had, on average, 2.5
exacerbations in the previous 2 years, with all having had at
least 2. Subjects were stratified by concomitant use of
inhaled corticosteroids (ICS), and by disease severity.
Over the 3-year period, there was no significant
difference in the rate of decline of FEV1 between the
treatment and the placebo groups. This observation held
regardless of underlying disease severity, and whether or
not concomitant ICS were used. Overall, there was no
significant difference in the annual exacerbation rates
between the NAC and the placebo groups; however, when
this was analyzed for the 155 subjects not taking ICS, there
was a significant benefit of NAC over placebo, with
respective rates of 0.96 per year vs 1.29 per year (p=0.040).
Subjects not on ICS had fewer moderate or severe
exacerbations with mucolytic therapy than with placebo
(p=0.032).
A multicenter RCT using ambroxol 75mg or placebo
for 1 year in 242 patients with COPD also evaluated the
effect on exacerbations (Malerba et al 2004). Concomitant
use of ICS was forbidden in this study. The mean age of the
subjects was 61 years and they had a mean FEV1 of 2.1L.
Subjects had had a mean of 2.7 exacerbations in the past
year. This study showed no overall difference in the number
of subjects who were exacerbation-free in the 2 groups,
although there were fewer exacerbations in total in the
ambroxol treated group than in the placebo group (79 vs
103). Post hoc analysis showed that subjects with more
severe symptoms who were treated with ambroxol were
more likely to be exacerbation-free (p=0.038) through the
study period.
A third RCT studied the effect of 300mg twice daily of
erdosteine, a synthetic thiol compound with effects on
bacterial adhesiveness, and with antioxidant and mucolytic
properties (Moretti et al 2004). Investigators in 9 Italian
centers enrolled a total of 155 subjects with COPD. 124
subjects completed the 8-month trial. The investigators
permitted concomitant ICS therapy but did not report on
the number of subjects using this therapy. Subjects had a
mean age of 67 years, were predominantly male, and had
mean FEV1 of 59% predicted. The study is the only large
study to show a beneficial effect of a mucolytic on lung
function decline with a reported difference of around 300ml
between the 2 groups at the end of the study (p<0.01).
Erdosteine treatment was associated with greater likelihood
of being exacerbation-free and fewer exacerbations than
placebo treatment. Hospitalization rates were nearly halved
in the erdosteine group. There were also statistically and
clinically significant improvements in 6 minute walk
distance and health-related quality of life scores.
Data from these 3 recent studies will inevitably result in
a revision of the Cochrane review estimate of the effect size
of mucolytic treatment on exacerbations in COPD. While
the actual effect size is difficult to determine, and will vary
depending on which studies are combined in meta-analysis,
there seems to be consistency in the evidence in 3 main areas:
(i) there is a significant and persisting effect of mucolytics
as a group on the total number of exacerbations; (ii)
regardless of the definition of COPD or CB, study subjects
seem to experience between 2 and 3 exacerbations in the
year prior to the study; (iii) those on mucolytics are more
likely to be exacerbation-free during the study period.
Mode of action of mucolytics
How mucolytic agents reduce exacerbations is not yet clear.
As a group they are heterogeneous in effects, and thus they
may act at different points in the inflammatory and oxidative
pathways that contribute to the development of COPD. The
role of oxidants in the pathogenesis of COPD (Rahman and
MacNee 1996) and exacerbations (Rahman et al 1997) is
increasingly being recognized. Several of the agents studied
in the Cochrane review (such as NAC, ambroxol, and
carbocysteine) have antioxidant properties. However, there
was a lack of an effect seen with NIC (a thiol donor derivative
of NAC) on exacerbations or days sick (Ekberg-Jansson et
al 1999). This finding argues against the actions of mucolytic
agents as thiol donors being the most important mechanism
in the reduction of exacerbations, although actions via other
antioxidant mechanisms are not excluded. Prolonged
treatment of COPD patients with 600 mg daily of NAC
reduces the production of H2O2 (a biomarker of oxidative
stress) compared with placebo (Kasielski and Nowak 2001).International journal of COPD 2006:1(2)
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In this study the effect on H2O2 exhalation was not seen
until at least 9–12 months of treatment, yet beneficial effects
of mucolytics on exacerbations have been seen in shorter
studies lasting for 3–6 months, again suggesting alternative
mechanisms. In another study treatment with NAC 600 mg
twice daily for 2 months in patients with stable COPD
resulted in a marked decline in breath H2O2 compared with
placebo (p=0.003) (De Benedetto et al 2005). This suggests
that dose is important for any antioxidant effect.
Mucolytics may work through antimicrobial and/or
immunostimulatory mechanisms. In CB, pretreatment with
NAC resulted in significantly fewer patients having positive
cultures from intrabronchial samples (Riise et al 1994). In
COPD, long-term treatment with NAC has been shown to
reduce the adhesion of neutrophils to cultured endothelial
cells (van Overveld et al 2000) and to enhance macrophage-
related killing of Staphylococcus aureus (Oddera et al 1994).
A RCT found that 6 months of treatment with NAC in adults
without chronic lung disease who had not received influenza
vaccination, was associated with a significant decrease in
incidence of influenza-like episodes than with placebo (29%
vs 51%, p=0.0006) (de Flora et al 1997). One of the few
approaches that has been shown to reduce COPD hospital
admissions is treatment with an immunostimulant bacterial
extract, OM 85 BV, or bronchovaxom (Collet et al 1997).
Other agents have been shown to reduce exacerbations
in COPD. The most convincing evidence of efficacy has
been presented for tiotropium, a long-acting anticholinergic
agent. The 2005 Cochrane systematic review of tiotropium
in COPD included 9 RCTs, with a total of 6584 patients
(Barr et al 2005). Meta-analysis showed that tiotropium
reduced the odds of a COPD exacerbation (OR 0.74, 95%
CI 0.66 to 0.83) and related hospitalization (OR 0.64, 95%
CI 0.51 to 0.82) compared with placebo or ipratropium. The
reviewers calculated that the number of patients needed to
treat with tiotropium for 1 year to prevent 1 exacerbation
was 14 (95% CI 11 to 22). Tiotropium also improved
symptoms and quality of life, benefits that have not been
shown with mucolytics.
The strongest evidence that the use of ICS reduces
exacerbation frequency comes from the ISOLDE trial in
which 751 men and women aged between 40 and 75 years
with severe COPD (mean FEV1 <50% predicted normal)
were treated with 500μg fluticasone dipropionate twice daily
for 3 years or placebo (Burge et al 2000). In the ICS-treated
group exacerbations reduced from 1.32 per year to 0.99 per
patient per year (p=0.026), an absolute reduction of 0.33
exacerbations per year, or 25%. Subjects taking ICS also
had a slower decline in health status than those in the placebo
group. This finding has resulted in a Level A
recommendation for the use of inhaled steroids in people
with moderate or severe COPD and repeated exacerbations,
in the latest GOLD guideline (Pauwels et al 2005). In the
same document mucolytics as a group remain unsupported
as effective therapy in COPD receiving a level D
recommendation, although NAC receives a B level
recommendation. While the B level recommendation seems
justified on the strength of the evidence for NAC, the
BRONCUS study findings might prompt some qualification
of the support for NAC over other mucolytics, by suggesting
that the effect of NAC on exacerbations is seen only in
subjects who are not on ICS.
These recent clinical studies suggest that there may be
an interaction of effect on exacerbations between mucolytics
and ICS, and that use of ICS may obscure any beneficial
effect of the mucolytic. The comparative effects of 10 weeks
of fluticasone 1000μg/day and NAC 600mg on markers of
inflammation and oxidative stress in subjects with COPD
have been reported recently (Sadowska et al 2005). NAC
decreased IL-8 levels via pathways not involving whole
blood glutathione peroxidase or plasma antioxidant activity.
Fluticasone did not affect IL-8 levels, but led to a significant
increase in antioxidant activity of glutathione peroxidase
and plasma antioxidants. These findings suggest, as would
be predicted, that the two agents act differently. More
research is needed to unravel the complex series of events
in the pathogenesis of COPD and exacerbations, and relative
effectiveness of agents or combinations of agents. At a
clinical level the relative effectiveness of mucolytics vs
tiotropium or ICS on exacerbations has not yet been studied.
RCTs comparing treatment arms of combination and single
agent therapy are warranted.
Mucolytics do not appear to have any convincing effect
on lung decline in COPD. The extent to which lung mucus is
associated with lung function decline in COPD remains
controversial, although a relationship between the two has
been shown (Vestbo et al 1996). Because oxidative stress
plays a major role in the pathogenesis of COPD (Rahman
and MacNee 1996), it was hoped that antioxidants might be
beneficial in terms of disease modification through reduction
of this stress. The oxidants derive from inhaled cigarette
smoke, as well as from tissue macrophages, and neutrophils.
If there were a role, it would seem desirable to use mucolytic
agents relatively early in the course of the disease while lung
function is relatively preserved. The study that had the greatest
power to show this (Decramer et al 2005) did not show anyInternational Journal of COPD 2006:1(2) 127
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effect of 600mg NAC daily on FEV1 decline in a patient
population with relatively mild disease. Nor was there any
effect of NAC in the more severe COPD subgroup. The
authors commented that there was small reduction in FRC
seen with NAC which may have occurred through an effect
on the small airways. They also propose that the dose of NAC
may not have been high enough. There is a recent report of
study involving 198 patients with pulmonary fibrosis
(Demedts et al 2005) showing a small but significant
preservation of lung function in the group treated with NAC
600mg 3 times daily for 1 year in addition to usual therapy,
compared with the group treated with placebo. Clearly the
effect of NAC in this disorder is not due to mucolytic
properties.
Conclusions
A cost-effectiveness analysis of NAC in CB was performed
retrospectively (Grandjean et al 2000a). This was based on
direct costs of NAC treatment and management of an acute
exacerbation, and indirect costs of sick leave. This suggested
that the point at which the costs of treatment and nontreatment
were equal was when there was a reduction of 0.6
exacerbations per 6-month period. In the Cochrane review,
the overall effect size was a reduction of about 0.4 per 6-
month period, suggesting that it would not be cost-effective
to treat everyone with COPD with mucolytics.
In their favor, mucolytic agents are safe and very well
tolerated with no suggestion from any of the RCTs over 2
months in duration of an increase in adverse effects over
placebo. The question of compliance also needs to be
considered, as patients would need to take these agents at
least daily through the winter months. However, for some
patients they may be easier to take than regular inhaled doses
of tiotropium or ICS. A further role might be in patients with
frequent exacerbations who have adverse effects from these
other agents. It is, of course, important to remember that
tiotropium improves symptoms whereas mucolytics and ICS
will have only a slight effect, if any.
The relative costs of the treatments and medicine
availability are other considerations. In New Zealand,
tiotropium 18μg daily is more than double the price of either
fluticasone 500 μg/day or the only available mucolytic in
tablet form, bromhexine (Adis International 2003).
As there is no evidence of significant disease modification
with these agents, treating everyone with COPD with
mucolytics is not warranted. The aim of regular treatment
with mucolytic agents should be to reduce exacerbations in
patients with moderate or severe COPD who have frequent
or prolonged exacerbations, or those who are repeatedly
admitted to hospital. They might be considered in patients
who are unable to take tiotropium or ICS for whatever reason.
The evidence is strongest for the use of NAC 600mg daily
for at least 3 months of the year, including the winter months.
Whether there are add-on benefits of mucolytic agents to these
other medicines is not yet known. Studies to address this, as
well as the optimum dose and duration of therapy with agents
such as NAC will be helpful in developing a greater range of
effective therapies and a better understanding of the
pathogenesis of COPD.
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